With the support of over 1,600 highly skilled R&D professionals, Hansoh has successfully developed multiple internally discovered drug candidates into NMPA-approved innovative medicines, including aumolertinib (), a third-generation EGFR inhibitor for the treatment of NSCLC with EGFR mutations
Always consult a licensed healthcare provider before beginning any new injection, infusion or supplement program, especially if you have underlying health conditions or take prescription medications
Dose size alone cannot override underlying physiology or medical risk
Larsen et al
Maltodextrin is a carbohydrate produced by the hydrolysis of starch that is optionally derived from corn, potato, wheat, or other plant products
doi: 10.3389/fcvm.2022.860322